Boston Scientific CORP 10-Q quarterly reports

Boston Scientific announced robust financial performance for the second quarter of 2026, driven by significant net sales growth and improved net income, alongside strategic acquisition updates.

Boston Scientific reported a significant 20.3% increase in Q3 2025 net sales and a 59.4% rise in diluted EPS, driven by robust commercial execution and strategic acquisitions.

Boston Scientific Corporation announced robust financial results for the second quarter and first half of 2025, driven by significant sales growth across its MedSurg and Cardiovascular segments, bolstered by recent strategic acquisitions and the successful launch of new medical technologies.

Boston Scientific's Q1 2025 net sales increased by 20.9% to $4.663 billion, fueled by strong performance in Electrophysiology and contributions from recent acquisitions.

Boston Scientific's Q3 2024 results show significant revenue growth, fueled by new product adoption and strategic acquisitions, despite some foreign currency headwinds.

Boston Scientific's second quarter results show a significant increase in net sales, driven by strong commercial execution and the rapid adoption of their Farapulse Pulsed Field Ablation System.

Boston Scientific's first quarter of 2024 saw a significant increase in net sales and adjusted earnings per share, boosted by strong performance across its product portfolio and recent acquisitions.